Search results for "mines"

showing 10 items of 2609 documents

Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans

2006

Abstract Objective The number of active pharmaceutical ingredients (API) undergoing inhibitable and saturable intestinal efflux is considerable. As a consequence, absorption and bioavailability may depend on the intestinal concentration profile of the drug and may vary as a function of dose and release rate of the drug from the dosage form. The impact of controlled versus immediate-release on the absorption of P-glycoprotein substrates is currently unknown. Thus, the main focus of the present study was a comparison of the pharmacokinetics of the P-gp model substrate talinolol following administration of immediate-release (IR) and controlled-release (CR) tablets to healthy human volunteers w…

AdultMaleActive ingredientChemistryPharmaceutical ScienceAbsorption (skin)PharmacologyCrossover studyControlled releaseDosage formBioavailabilityPropanolamineschemistry.chemical_compoundIntestinal AbsorptionSolubilityPharmacokineticsDelayed-Action PreparationsHumansFemaleATP Binding Cassette Transporter Subfamily B Member 1TabletsTalinololEuropean Journal of Pharmaceutical Sciences
researchProduct

Correlation of the chemiluminescence-activity of peripheral blood monocytes with CSF parameters of inflammation and the clinical course of patients w…

2009

– The chemiluminescence-activity (CL-A) of peripheral blood monocytes (MO) was measured in eight patients with lymphocytic meningitis or meningoencephalitis and compared to CSF parameters and the clinical course. The initial maximum CL-A was around four times above the control and decreased to normal values within approximately 20 days. Poor correlations were found when the CL-A was compared to CSF parameters in the total group of patients. With regard to the CSF parameters in individual patients the CL-A was closely related to the cell count, to a lesser degree to the protein content, but not to the IgG content. Finally, a very good correlation of the CL-A was found with the clinical cours…

AdultMaleAdolescentInflammationMonocyteslaw.inventionProtein contentCorrelationlawMeningoencephalitismedicineHumansMeningitisLymphocytesChildChemiluminescenceCerebrospinal Fluidbusiness.industryClinical courseMeningoencephalitisCerebrospinal Fluid ProteinsGeneral Medicinemedicine.diseasePeripheral bloodLymphocytic meningoencephalitisNeurologyImmunoglobulin GImmunologyLuminescent MeasurementsFemaleNeurology (clinical)medicine.symptombusinessActa neurologica Scandinavica
researchProduct

A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine

2011

The objective of this study was to evaluate patients’ satisfaction with acute treatment of migraine with frovatriptan or almotriptan by preference questionnaire. One hundred and thirty three subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or almotriptan 12.5 mg, treating 1–3 attacks. The study had a multicenter, randomized, double blind, cross-over design, with treatment periods lasting <3 months. At study end patients assigned preference to one of the treatments using a questionnaire with a score from 0 to 5 (primary endpoint). Secondary endpoints w…

AdultMaleAdolescentOriginalMigraine with AuraPopulationAlmotriptanCarbazolesClinical NeurologyMigraine; almotriptan; FrovatriptanYoung Adultalmotriptan; frovatriptan; migraine; patient preferenceDouble-Blind MethodAlmotriptanmedicineHumansMigraine Frovatriptan Almotriptan Patient preferencePatient preferenceeducationMigraineAgededucation.field_of_studyCross-Over Studiesbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseCrossover studyRizatriptanTryptaminesMigraine with auraSerotonin Receptor AgonistsalmotriptanTreatment OutcomeAnesthesiology and Pain MedicineItalyMigraineTolerabilityAnesthesiaAcute DiseaseFemaleSettore MED/26 - NeurologiaNeurology (clinical)medicine.symptombusinessFrovatriptanFrovatriptanmedicine.drug
researchProduct

Association between reduced lymphocyte beta-adrenergic receptors and left ventricular dysfunction in young obese subjects

1994

This study was designed to evaluate total (t) and surface (s) beta-adrenergic receptors (BAR) density and their relationships with left ventricular function in young obese subjects. BAR density, plasma insulin, catecholamines and left ventricular function were evaluated in 27 young obese subjects (BMI30.5 kg/m2 for males and27.3 kg/m2 for females) without other risk factors for cardiovascular diseases (smoking, hypertension, diabetes and lipid abnormalities) and in 20 lean controls (BMI25 kg/m2 for males and24.7 kg/m2 for females). Both groups were matched for gender, age and body height. BAR density was evaluated according to Böyum and De Blasi methods. Plasma catecholamines by high perfus…

AdultMaleAgingSettore MED/09 - Medicina InternaRadioimmunoassayPeripheral obesity Central Obesity lymphocyte beta adrenergic receptors left ventricular functionStroke VolumeSettore MED/11 - Malattie Dell'Apparato CardiovascolareVentricular Function LeftCatecholaminesEchocardiographyReceptors Adrenergic betaHumansInsulinRegression AnalysisFemaleLymphocytesObesityCardiac OutputRadionuclide AngiographyChromatography High Pressure Liquid
researchProduct

Premature ejaculation: Pharmacotherapy vs group psychotherapy alone or in combination

2017

Objectives: Premature Ejaculation (PE), the commonest sexual dysfunction in males, is generally treated with local anesthetic and SSRI (Dapoxetine). The aim of our study was investigate Group Psychotherapy as an alternative treatment for PE and compare the efficacy of pharmacological treatment and psychotherapy, either alone or in combination, in terms of response and improved Quality of Life (QoL). From a male outpatient population screened for PE, those who received a diagnosis of PE were proposed for the study, enrolled and divided into 3 groups (A, B and C). Each group was treated with Dapoxetine, Group Psychotherapy alone and Dapoxetine and Group Psychotherapy, respectively. Materials …

AdultMaleBenzylaminesmedicine.medical_specialtyEjaculationUrologymedicine.medical_treatmentPopulation030209 endocrinology & metabolismNaphthaleneslcsh:RC870-923Settore MED/24 - UrologiaGroup psychotherapyYoung Adult03 medical and health sciences0302 clinical medicineQuality of lifeGroup psychotherapyInternal medicinePremature ejaculationHumansMedicineeducationPsychiatryAgedPremature ejaculationeducation.field_of_studybusiness.industryMiddle Agedlcsh:Diseases of the genitourinary system. UrologyDapoxetineCombined Modality TherapyPsychotherapyDapoxetineSexual therapySexual dysfunctionPsychotherapy GroupAnxietymedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugArchivio Italiano di Urologia e Andrologia
researchProduct

Influence of green and black tea on folic acid pharmacokinetics in healthy volunteers: potential risk of diminished folic acid bioavailability

2008

Previous in vitro studies using Caco-2 cell monolayers suggested a possible interaction between green and black tea and folic acid at the level of intestinal absorption. The main purpose of the present study was to investigate a possible pharmacokinetic interaction between tea and folic acid in healthy volunteers. In an open-labeled randomized cross-over study, the pharmacokinetic interaction between tea and folic acid (0.4 mg and 5 mg) was investigated in healthy volunteers. Water was used as the reference drink. Subjects ingested 0.4 mg folic acid tablets with water, green or black tea (0.3 g extract/250 ml) or 5 mg folic acid tablets with water or green tea (0.3 g extract/250 ml). Blood …

AdultMaleBiological AvailabilityPharmaceutical SciencePharmacologyIntestinal absorptionFood-Drug InteractionsFolic AcidPharmacokineticsIn vivoHumansPharmacology (medical)Black teaImmunoassayPharmacologyCross-Over StudiesDose-Response Relationship DrugTeaChemistryfood and beveragesGeneral MedicineMiddle AgedCrossover studyBioavailabilityDose–response relationshipFolic acidArea Under CurveLuminescent MeasurementsVitamin B ComplexFemaleBiopharmaceutics &amp; Drug Disposition
researchProduct

The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing

2004

Budesonide/formoterol in a single inhaler is an effective therapy for asthma. We investigated whether adjustable maintenance dosing with budesonide/formoterol could maintain health-related quality of life (HRQL) and asthma control.Asthma patients (n = 4025) received budesonide/formoterol (Symbicort 160/4.5 microg) 2 inhalations twice daily (b.i.d.) for 4 weeks during run-in of this open, multicentre study. Patients were randomised to adjustable dosing (budesonide/formoterol 1 inhalation b.i.d.; stepping up to 2 or 4 inhalations bid for 1 week if asthma worsened) or fixed dosing (budesonide/formoterol 2 inhalations b.i.d.), for 12 weeks. Change in HRQL (standardised Asthma Quality of Life Qu…

AdultMaleBudesonideAdolescentDrug Administration Scheduleimmune system diseasesFormoterol FumarateAdministration InhalationmedicineHumansAnti-Asthmatic AgentsMetered Dose InhalersDosingBudesonideAgedAsthmaInhalationbusiness.industryInhalerGeneral MedicineMiddle Agedmedicine.diseaseAsthmaRespiratory Function Testsrespiratory tract diseasesDrug CombinationsTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaQuality of LifeFemaleFormoterol FumarateFormoterolbusinessmedicine.drugCurrent Medical Research and Opinion
researchProduct

Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study

2012

SummaryBackgroundStudies with inhaled corticosteroids (ICS) in smoking asthmatics have mostly shown poorer treatment responses than in non-smoking asthmatics.MethodsEuroSMART, an open, randomised, 6-month study, compared budesonide/formoterol (Symbicort ® Turbuhaler®)hhNeither the Symbicort SMART posology nor the dry powder formulation, Turbuhaler, is currently approved in the US. maintenance and reliever therapy (Symbicort SMART®) at two maintenance doses of budesonide/formoterol (160/4.5 μg), 1 × 2 and 2 × 2, in patients with asthma who were symptomatic despite treatment with ICS ± long-acting β2-agonists. The 8424 randomised patients included 886 smokers (11%; aged <40 years or with a sm…

AdultMaleBudesonidePulmonary and Respiratory MedicineSymbicort SMARTmedicine.medical_specialtyPeak Expiratory Flow RatePropensity-matched controlsDrug Administration Schedulelaw.inventionACQ-5Budesonide/formoterol maintenance and reliever therapyPharmacotherapyRandomized controlled triallawFormoterol FumarateSurveys and QuestionnairesInternal medicineAdministration InhalationmedicineHumansAnti-Asthmatic AgentsDosingBudesonideAsthmaSmokersDose-Response Relationship Drugbusiness.industrySmokingmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaDisease ProgressionDrug Therapy CombinationFemaleFormoterol FumarateFormoterolbusinessmedicine.drugRespiratory Medicine
researchProduct

The use of esmolol in whole-body hyperthermia: Cardiovascular effects

1997

Whole-body hyperthermia (WBH) is a well-described investigational adjunct to systemic chemotherapy for the treatment of advanced malignancies. The hemodynamic consequences of this physiologic state may include tachycardia, which can produce acute myocardial ischemia in patients with coronary artery disease. Ischemic heart disease is currently considered a contraindication to WBH. We chose to investigate the consequences of using a new beta 1-adrenergic antagonist, esmolol, to attempt to control the tachycardia associated with WBH. After institutional approval and patient consent, nine consecutive patients with normal cardiac function presenting for WBH with carboplatin infusion were studied…

AdultMaleCancer ResearchMean arterial pressureCardiac outputHeart diseasePhysiologySinus tachycardiaAdrenergic beta-AntagonistsCardiac indexAntineoplastic AgentsCoronary DiseaseCarboplatinPropanolaminesHeart RateNeoplasmsTachycardiaPhysiology (medical)Heart rateHumansMedicineInfusions Intravenousbusiness.industryContraindicationsHemodynamicsHyperthermia InducedMiddle Agedmedicine.diseaseEsmololCombined Modality TherapyAnesthesiaHeart failureFemaleSafetymedicine.symptombusinessmedicine.drugInternational Journal of Hyperthermia
researchProduct

Reference interval determination for N-terminal-B-type natriuretic peptide (NT-proBNP): A study in blood donors

2005

We assessed reference values in a group of apparently healthy blood donors. A total of 1980 blood donors was recruited and tested for the presence of NT-proBNP using a newly developed electrochemiluminescence immunoassay (ECLIA) method. NT-proBNP clustered in all blood donors below the age of 50 years and an upper limit of normal (ULN) was found to be 84 pg/ml for males and 146 pg/ml for females. Mean NT-proBNP values increased with increasing age which was due to an increasing number of individuals exceeding the ULN. Age- and gender-appropriate NT-proBNP levels decreased with increasing hemoglobin levels. Hemoglobin but not creatinine levels influenced the NT-proBNP concentration in this c…

AdultMaleCardiac function curvemedicine.medical_specialtyLuminescenceAdolescentmedicine.drug_classClinical BiochemistryRenal functionBlood DonorsHemoglobin levelsBiochemistryHemoglobinschemistry.chemical_compoundSex FactorsReference ValuesInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumanscardiovascular diseasesAgedImmunoassayCreatinineBiochemistry (medical)Age FactorsGeneral MedicineMiddle AgedPeptide FragmentsEndocrinologychemistryCreatinineReference valuesCohortFemaleHemoglobinhormones hormone substitutes and hormone antagonistsClinica Chimica Acta
researchProduct